List view / Grid view
22 November 2022 | By Thermo Fisher Scientific
Watch on-demand to learn how Sanofi utilises online process mass spectrometry for continuous respiratory gas analysis to improve process insight and drive better outcomes.
Many bacterial species have been found to exist in a viable but non-culturable state. Jeanne Moldenhauer discusses this phenomenon and makes suggestions as to why we don’t often see an increase in viable cells when using viability-based methods.
This application note compares Sartorius' Microsart AMP Mycoplasma kit with two other mycoplasma detection kits that are also based on DNA isolation with subsequent real-time PCR analysis.
A 3D bioprinting technique could, in the future, allow the creation of human tissue structures for the analysis of various diseases...
Groundbreaking technology could help soldiers on the battlefield and people with skin disorders...
Scientists have succeeded in printing 3D structures with living cells, this enables the production of micro building blocks that are viable and can be used for repairing damaged tissue...
Researchers believe they have a way to create the structural framework for growing living tissue using an off-the-shelf 3-D printer...
BMG LABTECH, Inc. - the Microplate Reader Company - and InvivoSciences, Inc. - a leader in stem cell tissue engineering providing a novel solution in first-in-class drug discovery - announced today a strategic collaboration to market the time-dependent fluorescent assessment of engineered 3D heart tissues using advanced microplate reader technologies.…
18 November 2013 | By AMSBIO
Presented by Dr Elad Katz, a senior scientist at AMSBIO, a new on-demand webinar explores the potential of 3D cell-based models for regenerative medicine and drug discovery.
A novel solution for analyzing 3D cell cultures, based on Tecan’s Infinite® M200 PRO and InSphero’s 3D InSight™ microtissue technology, is helping to reduce the cost of early phase drug development.
18 December 2012 | By Terry McCann, TJM Consultancy
The average cost to a major pharmaceutical company of developing a new drug is over USD 6 billion1. Herper1 observes that the pharmaceutical industry is gripped by rising failure rates and costs, and suggests that the cost of new drugs will be reduced by new technologies and deeper understanding of…
30 October 2012 | By kdm communications limited
Tecan and TAP Biosystems, a leading supplier of innovative cell culture systems, have announced a co-marketing agreement to further expand the automated 3D cell culture capabilities of the Freedom EVO® liquid handling platform. Automation of TAP’s collagen-based RAFT™ cell culture system will allow scientists to quickly and conveniently create 3D…
Tecan has signed a co-marketing agreement with Reinnervate, a leading company in the 3D cell culture market, to develop a range of automated solutions based on the Freedom EVO® liquid handling workstations and Reinnervate’s Alvetex®Scaffold 3D cell culturing technology.
19 June 2008 | By Dr Stefan Przyborski, Chief Scientific Officer, ReInnervate Ltd, School of Biological and Biomedical Science, Durham University
Cell culture assays play an important role during the first stages of pharmaceutical development. The design of such in vitro models is significant and data resulting from such tests directly influences the progression of compound development. Therefore it is becoming progressively more important to design cell culture assays that are…
